IFNA1 and STING-associated vasculopathy with onset in infancy: These conditions have a very strong IRG signature and blocking IFN signaling with a Janus kinase (JAK) inhibitor correlates with clinical improvement and IRG-S decrease in the majority of 18 CANDLE and SAVI patients, with 50% of CANDLE patients achieving persistent clinical remission [16, 18–20].